consults for and advises AstraZeneca and Avant Sant, consults for and has received grants from Akero, Bristol Myers Squibb, Eli Lilly, Intercept, Madrigal and Novo Nordisk, consults for and owns stock in Rivus, consults for 89bio, AGED Diagnostics, Albireo, Alnylam, Altimmune, Boehringer Ingelheim, Echosens, Genentech, Gilead, GlaxoSmithKline, HistoIndex, Mallinckrodt, Merck, NGM Bio, Novartis, PathAI, Pfizer, Poxel, Regeneron, Salix, Siemens, Surrozen, Takeda, Terns and Zydus, owns stock in Durect, Exalenz, Genfit, Indalo, Inversago and Tiziana, and has received royalties from Elsevier and Wolters Kluwer
Unfortunately, pharmacological inhibitors specific for NNT have not been reported and need to be developed
Wound healing has become more than a theoretical concern for GLP-1 patients, with surgeons increasingly reporting post-op complications, because of nutritional deficiencies in Ozempic patients and the way these can compromise wound healing and collagen in the skin
Possible allergic reactions: This is typically temporary and can be managed by lying down or sitting with the head between the knees